ATE538136T1 - Antikörper gegen connective tissue growth factor - Google Patents

Antikörper gegen connective tissue growth factor

Info

Publication number
ATE538136T1
ATE538136T1 AT04753822T AT04753822T ATE538136T1 AT E538136 T1 ATE538136 T1 AT E538136T1 AT 04753822 T AT04753822 T AT 04753822T AT 04753822 T AT04753822 T AT 04753822T AT E538136 T1 ATE538136 T1 AT E538136T1
Authority
AT
Austria
Prior art keywords
growth factor
antibodies against
connective tissue
tissue growth
antibodies
Prior art date
Application number
AT04753822T
Other languages
English (en)
Inventor
Ai Lin
Thomas Neff
Noelynn Oliver
William Usinger
Qingjian Wang
David Yeowell
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE538136T1 publication Critical patent/ATE538136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
AT04753822T 2003-06-04 2004-06-02 Antikörper gegen connective tissue growth factor ATE538136T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47559803P 2003-06-04 2003-06-04
US10/858,186 US7405274B2 (en) 2003-06-04 2004-06-01 Connective tissue growth factor antibodies
PCT/US2004/017080 WO2004108764A2 (en) 2003-06-04 2004-06-02 Connective tissue growth factor antibodies

Publications (1)

Publication Number Publication Date
ATE538136T1 true ATE538136T1 (de) 2012-01-15

Family

ID=33493433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04753822T ATE538136T1 (de) 2003-06-04 2004-06-02 Antikörper gegen connective tissue growth factor

Country Status (16)

Country Link
US (9) US7405274B2 (de)
EP (3) EP2322549A1 (de)
JP (2) JP5624707B2 (de)
KR (1) KR101244113B1 (de)
CN (2) CN1829740B (de)
AT (1) ATE538136T1 (de)
AU (1) AU2004245514B2 (de)
BR (1) BRPI0410963B8 (de)
CA (1) CA2526509C (de)
DK (1) DK1631591T3 (de)
ES (1) ES2379662T3 (de)
IL (1) IL172328A (de)
NO (1) NO336451B1 (de)
NZ (1) NZ543522A (de)
RU (1) RU2330861C2 (de)
WO (1) WO2004108764A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
CN1187370C (zh) * 1998-12-14 2005-02-02 迈阿密大学 结缔组织生长因子片段及其方法和用途
PL1715890T3 (pl) 2004-02-11 2009-01-30 Fibrogen Inc CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
EP1742965B1 (de) 2004-04-28 2012-10-24 Fibrogen, Inc. Behandlungen von bauchspeicheldrüsenkrebs
AU2006244148A1 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Cardiovascular disease therapies
DE602006021600D1 (de) * 2005-09-29 2011-06-09 Fibrogen Inc Verfahren zur senkung des blutdrucks
JP2008295328A (ja) 2007-05-30 2008-12-11 Fujifilm Corp 卵巣癌の検出方法、及び抑制方法
JP2012502991A (ja) 2008-09-22 2012-02-02 アールエックスアイ ファーマシューティカルズ コーポレーション 皮膚適用におけるｒｎａ干渉
RU2392960C1 (ru) * 2008-09-26 2010-06-27 Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) Способ коррекции плотности соединительной ткани
WO2010042201A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of focal segmental glomerulosclerosis
WO2010042202A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
EP2221387A1 (de) * 2009-02-19 2010-08-25 Université de la Méditerranée Fibroseanfälligkeitsgen und Verwendungen davon
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
US8771692B2 (en) * 2009-07-02 2014-07-08 Fibrogen, Inc. Methods for treatment of muscular dystrophy
WO2011056234A1 (en) * 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
EP3560503B1 (de) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna-interferenz bei dermalen und fibrotischen erkrankungen
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
US20140065162A1 (en) * 2011-11-08 2014-03-06 Fibrogen, Inc. Compositions and Methods for Treating Brain Tumors
PT2796550T (pt) * 2011-12-22 2018-04-18 Astellas Pharma Inc Novo anticorpo ctgf anti-humano
JP6187960B2 (ja) * 2012-01-20 2017-08-30 日本製粉株式会社 がんの治療又は予防剤
US20150147340A1 (en) * 2012-03-30 2015-05-28 Fibrogen, Inc. Therapeutic methods for peritoneal carcinomatosis
EP2844291B1 (de) 2012-05-03 2019-02-13 Fibrogen, Inc. Verfahren zur behandlung von idiopathischer lungenfibrose
US10039770B2 (en) * 2013-09-26 2018-08-07 Galderma S.A. Prostaglandin F2Alpha and analogues thereof for treating atrophic cutaneous scarring
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CN104740628B (zh) * 2015-02-12 2017-09-26 西安交通大学医学院第一附属医院 用于治疗肝纤维化的结缔组织生长因子嵌合疫苗及其应用
CN107922485A (zh) 2015-06-15 2018-04-17 斯坦福大学托管董事会 诊断和治疗情绪障碍的方法
EP3386544B1 (de) * 2015-12-10 2020-11-25 Fibrogen, Inc. Verfahren zur behandlung von motoneuronenerkrankungen
CN109415730A (zh) 2016-06-13 2019-03-01 北卡罗来纳大学教堂山分校 优化的cln1基因和表达盒以及它们的应用
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
JP7264382B2 (ja) * 2018-05-17 2023-04-25 オリーブス バイオセラピューティクス インコーポレイテッド 網膜疾患を予防又は治療するための、有効成分としてｃｃｎ５を含む医薬組成物
WO2020009248A1 (ja) * 2018-07-04 2020-01-09 京都府公立大学法人 眼組織の線維化抑制用組成物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
TW202110880A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 抗結締組織生長因子抗體及其應用
EP3821946A1 (de) * 2019-11-12 2021-05-19 Université de Strasbourg Monoklonale anti-claudin-1-antikörper zur prävention und behandlung von fibrotischen erkrankungen
CN115286713B (zh) * 2020-10-27 2024-07-23 温州医科大学 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
AU2021390125A1 (en) * 2020-12-03 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
CN115645525B (zh) * 2022-12-14 2023-04-14 北京大学第三医院（北京大学第三临床医学院） Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用
WO2024188179A1 (zh) * 2023-03-10 2024-09-19 上海济煜医药科技有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用
US12121561B1 (en) 2024-02-17 2024-10-22 King Faisal University Composition for treating or preventing insulin resistance

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587670A (en) 1897-08-03 Combined high-pressure throttle and reducing valve
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DK0783243T3 (da) 1994-09-15 2001-06-18 Fred Nordberg Indretning til elektrisk hegn
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
JPH11180895A (ja) * 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
WO1999033878A1 (en) 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
CN1326361A (zh) 1998-09-08 2001-12-12 亨利福特保健系统公司 通过修饰、调节及抑制结缔组织生长因子来检查、预防和治疗肾脏疾病的方法
US6348329B1 (en) 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
CN1187370C (zh) * 1998-12-14 2005-02-02 迈阿密大学 结缔组织生长因子片段及其方法和用途
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1434993B1 (de) * 2001-09-18 2013-04-24 Fibrogen, Inc. Verfahren zum testen des bindegewebe-wachstumsfaktors
EP1463531B1 (de) 2001-12-11 2011-09-28 Fibrogen, Inc. Verfahren zur hemmung okularer vorgänge
US20190127456A1 (en) * 2017-10-31 2019-05-02 Fibrogen, Inc. Methods of treating idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
NO336451B1 (no) 2015-08-24
DK1631591T3 (da) 2012-04-10
NO20060027L (no) 2006-01-03
WO2004108764A2 (en) 2004-12-16
CA2526509A1 (en) 2004-12-16
BRPI0410963B8 (pt) 2021-05-25
CN1829740A (zh) 2006-09-06
US7405274B2 (en) 2008-07-29
BRPI0410963B1 (pt) 2019-10-08
US20240076364A1 (en) 2024-03-07
US9034643B2 (en) 2015-05-19
US20110091468A1 (en) 2011-04-21
US20210230259A1 (en) 2021-07-29
NZ543522A (en) 2008-06-30
JP5753506B2 (ja) 2015-07-22
EP2338914A1 (de) 2011-06-29
CN1829740B (zh) 2013-05-29
RU2005141492A (ru) 2007-07-20
WO2004108764A3 (en) 2005-03-03
IL172328A (en) 2012-01-31
AU2004245514A1 (en) 2004-12-16
CA2526509C (en) 2013-08-06
EP1631591B1 (de) 2011-12-21
US20090017043A1 (en) 2009-01-15
ES2379662T3 (es) 2012-04-30
JP2012143239A (ja) 2012-08-02
EP1631591A2 (de) 2006-03-08
EP2322549A1 (de) 2011-05-18
BRPI0410963A (pt) 2006-07-04
CN103539858A (zh) 2014-01-29
JP5624707B2 (ja) 2014-11-12
KR20060030032A (ko) 2006-04-07
US20140073047A1 (en) 2014-03-13
US20160257740A1 (en) 2016-09-08
US20040248206A1 (en) 2004-12-09
US20160024198A1 (en) 2016-01-28
AU2004245514B2 (en) 2009-10-01
US7871617B2 (en) 2011-01-18
RU2330861C2 (ru) 2008-08-10
HK1094336A1 (zh) 2007-05-04
JP2007525194A (ja) 2007-09-06
KR101244113B1 (ko) 2013-03-18
US20190023778A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
ATE538136T1 (de) Antikörper gegen connective tissue growth factor
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
BRPI0307673A2 (pt) métodos de tratar doença vascular.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2006121610A3 (en) Personal care compositions and methods for their use
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
NO20076241L (no) Terapier for vaskulaere sykdommer
DK1411064T3 (da) Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
DE50311735D1 (de) Das tissue engineering von knochen
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
EE05099B1 (et) Bradkardiaalsete toimeainete kasutamine hpertroofiaga seotud mokardiaalsete haiguste ravimiseks ja ravimikombinatsioonid
EA200400399A1 (ru) Способы лечения легочных заболеваний
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
DE60327084D1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3-sulphonamid in der tumortherapie
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
RU2003102394A (ru) Способ лечения гнойно-воспалительных заболеваний мягких тканей у детей
HK1079709A1 (zh) 脱唾液酸-干扰素系及肝癌的治疗
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins
ITUD20030021A1 (it) Procedimento per la concia delle pelli e pelli cosi' ottenute.